Cullinan reports $439M cash as of Dec 31, 2025; outlines 2026 clinical milestones for CLN-978, CLN-049, zipalertinib

Cullinan Therapeutics, Inc.

Preliminary cash, equivalents, investments, interest receivable $439.0M at Dec 31, 2025; runway into 2029.
CLN-978: Phase 1 dose escalation in RA, SLE, SjD ongoing; initial data readouts in Q2/Q3/Q4 2026.
CLN-049: Fast Track for relapsed/refractory AML; dose expansion to determine RP2D in Q4 2026; pivotal trial expected.
Zipalertinib: NDA submission completion expected Q1 2026; REZILIENT3 enrollment complete H1 2026; $130M US milestones + 50% profit share.
Velinotamig: Genrix Bio Phase 1 in China initiated; initial data in Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.